Senior Vice President QSP Certara Sheffield, England, United Kingdom
The presentation will show: (1). How a QSP vaccine model has been developed and applied from concept to first regulatory submission in less than 6 months; - (2). How this has impacted several Covid-19 vaccine development programs; - (3). What this has taught us about (lack of) quantitative approaches in vaccine development and opportunities for Model-informed vaccine development (MIDD); - (4). How these lessons are now being applied in vaccine development for other infectious diseases and other therapeutic areas, including oncology and rare diseases.
Learning Objectives:
Upon completion, participants will have a better understanding of the role of QSP in (Covid-19) vaccine development
Upon completion, participants will have a better understanding of the critical role of platform development driving succes of QSP
Upon completion, participants will have a better understanding of the concept of model-informed vaccine development (MIVD)
